Author

Hai-Yan Liu

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Design and synthesis of novel peptide-based degraders against wild type and gatekeeper mutants FGFR1 for the treatment of NSCLC.

The feasibility of Pep-SignalTACs as a promising FGFR1-targeted therapeutic platform that enables effective degradation of both wild-type and mutant FGFR1 in NSCLC is demonstrated.

Zi-Yu Tian, Lu-Wei Fu, Xuan-Xuan Yan et al. · European journal of medicina... · 0 citations